Molecular interaction of *Survivin* and *Piperine* by computational docking analyses for neuroblastoma targeting

V. Muthukumar and A. J. Vanisree

Department of Biochemistry, University of Madras, Chennai - 600 025, INDIA

**KEY WORDS**
- Childhood cancer
- Alkaloid
- Apoptosis
- In-silico

**ABSTRACT**

**Background:** Neuroblastoma (NB) is a childhood cancer causing significant mortality in at least 1% children worldwide. NB is an embryonically derived tumor. The causative agents include genetic predisposition and dysregulated signaling cascades. *Survivin* is an important anti-apoptotic protein that is significantly up-regulated in NB. In this study, a naturally occurring ligand - *Piperine* was assessed for its interaction with *Survivin* protein.

**Purpose:** The study was undertaken in order to identify the experimental feasibility of *Survivin* inhibitor ligand *Piperine* as targeting treatment of NB. **Methods:** Protein sequences were retrieved and saved in PDB format. Similarly, the ligand data was processed using MGL (Molecular Graphics Laboratory) and chimera tools and saved in PDB format. Both protein and the ligand data were then uploaded to the docking server and docking parameters were set. **Results:** In-silico docking study of a protein ligand interaction resulted in $-3.36 \text{ Kcal/mol}$ free energy value for the ligand, with an involvement of 1 hydrogen bond, 7 hydrophobic interactions and 13 ionic interactions. The results were correlated with the existing free energy value of $>-3 \text{ Kcal/mol}$ which is established for a good inhibitor. **Conclusion:** The molecular docking study for mice *Survivin* and *Piperine* shows good inhibitory interaction effect and can, therefore, be considered as a molecule against *Survivin* enhanced tumor condition including NB.

**Corresponding Author:**
A. J. Vanisree, Ph.D
Tel.: +91-9444406262
E.mail : vanielango@gmail.com

---

**Introduction**

Computational docking minimizes the time consuming process of molecular analyses for selecting a suitable ligand which could be then applied for wet lab investigations.1 Wickbery and Co-workers used Bioinformatics to narrow down suitable ligands for biomedical research and drug design as structure based design shows precisely the location and orientation of bound inhibitors and their physico-chemical properties.2 *Survivin* is an apoptosis pathway inhibitor protein. It has important roles in cell cycle and cell proliferation. In normal embryonic development, expression of *Survivin* was found to be high and it was also expressed in some adult’s colonic epithelium, uterine, vascular endothelium and subventricular region of brain. In cancer cells, *Survivin* expression was found to be very high.3,4 Previous works reported that *Survivin* mainly works as an inhibitor of apoptosis, blocking mitochondrial dependent apoptosis5-8 (Figure 1). It was also reported later that it has other role as a mitotic checkpoint.9 *Survivin* family of proteins are involved in control of mitosis and makes perfect cell division in normal cells.10 It prevents the aneuploidy which normally occurs in malignant tissues.11 Neuroblastoma (NB) is a childhood cancer causing significant mortality of at least 1% of children worldwide. *Survivin* is known to be expressed at high levels in NB.12 *Piperine* is a heterocyclic alkaloid that belongs to a family of nitrogenous compounds with marked physiological properties. It is non-genotoxic, but found to have anti-mutagenic and anti-tumor activity.13

**Methods**

The current study was focused towards developing understanding of *Survivin*, which has been reported to be up regulated in NB and in certain other tumors.13 The PDB file of the protein was downloaded from RCSB (www.rcsb.org) which was then purified in a docking server. In the same server docking calculation were carried out. Also the ligand piperine, an alkaloid was drawn using ChemDraw tool v.4.0 and converted to PDB file format using MGL tool. The target protein and the ligand were subjected to docking.

Essential hydrogen atoms, Kollman united atom type charges, and salvation parameters were added with the aid of auto dock tools. The affinity (grid) map of XXÅ mid points 0.375Å spacing was generated using the autogrid program.15 Auto dock parameters were set on distance dependent dielectric Van-der-waals and the electro static terms respectively. Docking simulations were performed using the Lamarckian Genetic Algorithm (LGA) and the Solis and Wets local search method.16 Initial position, orientation and torsions of the ligand molecules were set randomly. All rotatable torsions were released during docking. Each docking experiment was derived

---

**Fig. 1:** Survivin Pathway.
from two different runs that were set to terminate after maximum of 25000 energy evaluations. The population size was set at 150. During the search, a translational step of 0.2Å and quaternion step of 5 were applied.\textsuperscript{17}

**Results**

Molecule docking of *Survivin* with ligand *Piperine* has an outcome of good energy level calculations that suit drug modeling of the ligand (Figure 2). Free energy ($\Delta G$) of $-3.36$ Kcal/mol, inhibition constant (K) of $3.42$ mM, and electrostatic energy of $-0.04$ Kcal/mol (Table 1) was noted.

The protein–ligand interaction study showed 6 amino acid residues interaction with the ligand (12:Leu, 20:Ala, 21:Thr, 44:Ile, 46:Cys, 56:Gln) (Table 2). The interaction of ligand and protein was generated and is depicted in HB plot (Figure 3).

**Discussion**

NB is a hidden health risk for both the public and the researchers. Therefore, a drug that can inhibit the disorder will be helpful in better health management.

The signaling cascade molecules in NB need to be analyzed computationally for better ligand. For this purpose molecular docking is an ideal tool.\textsuperscript{18} Faster and cheaper methods for drug designing at initial stages include molecular docking. In this study, the simulation of protein–ligand chemistry, binding and dissociation energy were focused upon. The energy and interaction details have been developed using Auto Dock. The free energy ($\Delta G$) of interaction is $-3.36$ Kcal/mol, which is in good agreement with physiological protein-ligand (hormones, enzymes) interaction range of $-2.00$ Kcal/mol to $-6.00$ Kcal/mol\textsuperscript{19} therefore; our result suggests a good candidate for protein–ligand interaction.

Inhibition constant (K) is an important force in molecular interaction. Obtained $K_{i}$\textsuperscript{20} is favorable towards developing a novel drug

| Table 1: Molecular docking energy level table |
|------------------------------------------|
| **Rank** | **Est. Free Energy of Binding** | **Est. Inhibition Constant, K** | **vdW + Hbond + desolv Energy** | **Electrostatic Energy** | **Total Inter-molec. Energy** | **Frequency** | **Interact. Surface** | **Download** |
|-------|-----------------|-----------------|-----------------------------|-----------------|-----------------------------|---------------|-----------------|---------------|
| 1     | $-3.36$ kcal/mol | $3.42$ mM       | $-4.15$ kcal/mol            | $-0.04$ kcal/mol| $-4.19$ kcal/mol            | 50%           | 512.417         | download      |
| 2     | $-3.09$ kcal/mol | $5.39$ mM       | $-4.09$ kcal/mol            | $+0.11$ kcal/mol| $-3.97$ kcal/mol            | 50%           | 512.053         | download      |

**Table 2: Protein and ligand interaction table of residues and atoms**

| Interaction Table |
|-------------------|
| Hydrogen bonds    | Hydrophobic       | Other               |
| N1 0              | GLN56            |                   |
| [3.02]            | (OE1)            |                   |
| C12 0             | LEU12            |                   |
| [3.20]            | (CD2)            |                   |
| O1 0              | ALA20            |                   |
| [3.43]            | (CB)             |                   |
| C13 0             | LEU12            |                   |
| [3.56]            | (CD2)            |                   |
| C15               | THR21            |                   |
| [3.44]            | (CB, CG, OG1)    |                   |
| C17 0             | ALA20            |                   |
| [3.70]            | (CB)             |                   |
| C11 0             | THR21            |                   |
| [3.70]            | (CG2, OG1)       |                   |
| C7 0              | ILE44            |                   |
| [3.18]            | (CD1)            |                   |
| C12 0             | THR21            |                   |
| [3.57]            | (OG1)            |                   |
| C6 0              | ILE44            |                   |
| [3.71]            | (CD1)            |                   |
| C13 0             | THR21            |                   |
| [3.42]            | (OG1)            |                   |
| C5 0              | ILE44            |                   |
| [3.59]            | (CD1)            |                   |
| C14               | THR21            |                   |
| [3.33]            | (OG1)            |                   |
| C1 0              | CYS46            |                   |
| [3.43]            | (CB, SG)         |                   |
| C16 0             | THR21            |                   |
| [3.38]            | (CG2, OG1)       |                   |
| C3 0              | GLN56            |                   |
| [3.15]            | (CD, OE1)        |                   |
| C6 0              | GLN56            |                   |
| [3.87]            | (OE1)            |                   |
| C4 0              | GLN56            |                   |
| [3.08]            | (OE1)            |                   |
| C5 0              | GLN56            |                   |
| [2.38]            | (OE1)            |                   |
| C1 0              | GLN56            |                   |
| [3.04]            | (OE1)            |                   |
molecule. Vander Waal’s force, hydrogen bonds are the other factors which stabilize ligand-protein interaction in our docking study, in which the results for electrostatic force of molecules were significantly less, and it is a sign of a good protein-drug interaction. Docking results give binding site analysis for 6 amino acids, with the ligand which shows precise conformity. Three polar residues and 3 non-polar residues reflect a stable electrostatic interaction. Even though there is a single H-bond, the electrostatic force obtained in the result is significant enough for a strong bonding in case of a protein-drug interaction.21 Also, the existence of rich number of ionic bond in the docking study suffices for a further more stable association. The ligand Piperine interacted well with the protein Survivin in the docking grid.

Conclusions
Molecular docking of surviving (mice) with ligand Piperine when subjected to docking analysis using AutoDock and docking server, predicted in-silico result with a free energy of –3.36 Kcal/mol which was agreed well with physiological range for protein-ligand interaction, making Piperine probable potent anti-survivin molecule. Therefore, it is expected that Piperine might participate by down regulating the levels of Survivin upon administration, making the NB cells pro-apoptotic, eventually leading to death of tumor cells.

The article complies with International Committee of Medical Journal Editor’s uniform requirements for the manuscripts.

Competing interests: None, Source of Funding: None

Received Date : 2 August 2011; Revised Date: 16 August 2011
Accepted Date : 25 August 2011

References
1. David S. Goodsell. Computational Docking of Biomolecular Complexes with AutoDock. Cold Spring Harb Protoc; 2009; doi:10.1101/pdb.prot5200
2. Proteochemometrics.org – A Site Dedicated to the Research of Proteochemometrics. http://www.proteochemometrics.org/ (accessed March 12, 2008)
3. Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod, 2000; 6: 529–34.
4. Gianani R, Jarboe E, Frost M, et al. Expression of Survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol, 2001; 32: 119–25.
5. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46–54.
6. Altura BA, Olshefski RS, Jiang Y, et al. Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer, 2003; 3: 89(9): 1743–9.
7. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by Survivin. Nature, 1998; 396: 580–4.
8. Altieri DC, Marchisio PC and Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest, 1999; 79: 1327–33.
9. Noton EA, Colnaghi R, Tate S, et al. Separating the anti-apoptotic and mitotic roles of Survivin. Bio. Chem, 2006; 44: 33450–6.
10. Lens SM, Coffey PJ, Burginger BM, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J, 2003; 22: 2934–47.
11. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-delta Ex3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br. J. Cancer, 2005; 92: 359–65.
12. Wang JX and Zheng S. Caspase-3 and Survivin expression in pediatric Neuroblastoma and their roles in apoptosis. Chin Med J (Engl), 2004; 117(12): 1821–4.
13. Srinivasan K. Black pepper and its pungent principle-Piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr, 2007; 47(8): 735–48.
14. Beerle EA, Nagaram A, Dai W, et al. VEGF stimulated expression of Survivin by Neuroblastoma cells is dependent upon AKT. Journal of Surgical Research, 2004; 121(2): 305.
15. Morris GM, Goodsell DS, Halliday RS, et al. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. Journal of Computational Chemistry, 1998; 19(14): 1639–1662.
16. Solis FJ and Wets RB. Minimization by Random Search Techniques. Mathematics of Operations Research - MOR, 1981; 6(1): 19–30.
17. Bikadi Z and Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of Auto Dock. J. Cheminf, 2009; 1: 15.
18. Berthold F and Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs, 2000; 59(6): 1261–77.
19. Kortemme T and Baker D. A Simple Physical Model for Binding Energy hot Spots in Protein-protein Complexes. Proc Natl Acad Sci USA 2002; 99: 14116–14121.
20. Toprakçı M and YelekçI K. Docking studies on monoamine oxidase-B inhibitors: Estimation of inhibition constants (K) of a series of experimentally tested compounds. Bioorganic & Medicinal Chemistry Letters, 2005; 15: 4438–4446.
21. Patil R, Das S, Stanley A, et al. Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing. PLoS ONE, 2010; 5(8): 1–10.